Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
86pct
39d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
H. Con. Res. 14/S. Con. Res. 7, the Budget Reconciliation Resolution S. 1096, the Preserving Access to Affordable Generics and Biosimilars Act. S. 1095, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act. S. 1040, the Drug Competition Enhancement Act. H.R. 9070/S. 1041, the Affordable Prescriptions for Patients Act. S. 1097, the Interagency Patent Coordination and Improvement Act of 2025. No bill number. Discussed pharmacy benefit managers. S. 527, Prescription Pricing for the People Act of 2025. S. 526, the Pharmacy Benefit Manager (PBM) Transparency Act of 2025. S. 229, the Drug-Price Transparency for Consumers (DTC) Act of 2025. No bill number. Discussed Medicare Part D. No bill number. Discussed cap on out-of-pocket prescription drug costs. No bill number. Discussed the Medicare Prescription Payment Plan. No bill number. Discussed the Medicare drug price negotiation program.
Referred to the Subcommittee on Oversight, Investigations, and Accountability.
Referred to the Subcommittee on Border Security and Enforcement.
Referred to the Committee on the Judiciary, and in addition to the Committee on Homeland Security, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $6,630,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
H. Con. Res. 14/S. Con. Res. 7, the Budget Reconciliation Resolution S. 1096, the Preserving Access to Affordable Generics and Biosimilars Act. S. 1095, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act. S. 1040, the Drug Competition Enhancement Act. H.R. 9070/S. 1041, the Affordable Prescriptions for Patients Act. S. 1097, the Interagency Patent Coordination and Improvement Act of 2025. No bill number. Discussed pharmacy benefit managers. S. 527, Prescription Pricing for the People Act of 2025. S. 526, the Pharmacy Benefit Manager (PBM) Transparency Act of 2025. S. 229, the Drug-Price Transparency for Consumers (DTC) Act of 2025. No bill number. Discussed Medicare Part D. No bill number. Discussed cap on out-of-pocket prescription drug costs. No bill number. Discussed the Medicare Prescription Payment Plan. No bill number. Discussed the Medicare drug price negotiation program.
Client expense: $6,630,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office